Q-omics provides the consensus-scored MIR520C profile across patient tissues and cancer cell-line models. MIR520C expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR520C is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, MIR520C RNA expression shows 6,386 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, THCA, and STAD as cancer lineages where MIR520C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR520C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR520C survival associations across molecular data types. MIR520C RNA expression shows survival associations in the most cancer types (8), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR520C RNA expression–survival associations across cancer types. High MIR520C expression shows unfavorable associations in CESC, PAAD, SKCM, SARC, KIRC and UCEC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify CESC as the clearest survival context for MIR520C RNA expression.
This table summarizes MIR520C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR520C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR520C shows lower tumor expression in THCA. The THCA box plot shows higher MIR520C RNA expression in normal versus tumor tissue (log2 FC = −0.077, t-test p = .012).
This table shows molecular features associated with MIR520C in patient tissues and cancer cell lines. In patient samples, MIR520C shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
